A Randomised Controlled Trial of Akynzeo® (Netupitant/Palonosetron) versus Standard Treatment for the Prevention of Post-Operative Nausea and Vomiting after Bariatric Surgery
Postoperative nausea and vomiting (PONV) is common in the setting of bariatric surgery and can be detrimental to patient recovery. Multimodal antiemetic strategies have been shown to be more effective than monotherapy to target the high incidence of PONV after laparoscopic surgery. This study seeks to evaluate the efficacy of Akynzeo® (netupitant/palonosetron) to prevent PONV in patients with morbid obesity following bariatric surgery.
Aim:
To determine if Akynzeo® is more effective than standard treatment for preventing PONV after laparoscopic bariatric surgery
To assess the cost-effectiveness and safety of Akynzeo® as a preventative treatment strategy.
Status: Currently recruiting
Site: St Vincent’s Private Hospital
Ethics: HREC/60961/SVHM-2020-219779
ANZCTR Registration: ACTRN1260000455965p
Principal Investigator: Mr Michael Hii/Dr Romy Granek
Eligibility
Inclusion
Adults ≥18 years of age
Undergoing elective laparoscopic sleeve gastrectomy or laparoscopic Roux-en-Y gastric bypass
Exclusion
Known allergy or on medication with known interactions with study drugs
Renal impairment
Significant psychiatric disease
Revision or robotic surgery
Outcome Measures
Post operative nausea and vomiting visual analogue scale (VAS)
Quality of Recovery after surgery and anaesthesia (QoR-15)
Records of rescue anti-emetics use
Adverse events
Overall Patient Satisfaction VAS